A Closer Look at IL-17 and IL-23 Inhibitors in the Treatment of Ankylosing Spondylitis: Individualizing Therapy for Improved Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

Improving the Clinical and Economic Burden of Ankylosing Spondylitis: Targeting IL17/IL-23 Pathways for Optimized Patient Outcomes is a 3-part live webinar series that will provide attendees
with the latest information in the management of AS

This is Part 2 of the series focusing on individualizing therapy in AS

This activity is an archive from the webinar held February 25, 2020

This activity is valid from April 1, 2020 to April 1, 2022

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Lilly and Novartis Pharmaceuticals Corporation

Ankylosing spondylitis (AS) is an immune-mediated chronic inflammatory disease that typically affects the sacroiliac (SI) joints. Patients with AS suffer from debilitating pain and joint fusion that severely limits their mobility and functional capacity. It is estimated that AS affects approximately 1.6 million people in the US. Due to an aging population, declining number of rheumatologists, and limited access to care, care for patients with AS is suboptimal and costly. Fortunately for patients with this disease, recent advances in pathogenesis have led to an increased understanding of the disease, which has subsequently led to the development of novel targeted agents shown to slow its progression, including options targeting IL-17/IL-23 pathways.

Upon completion of this activity, participants will be able to:

  • Recognize current challenges in classification and diagnosis of axial spondyloarthritis and ankylosing spondylitis (axSpA/AS)

  • Discuss unmet needs in the early recognition, diagnosis and management of axSpA/AS (including co-morbidities)

  • Explore the role of the IL-23/IL-17A axis in the pathogenesis of axSpA/AS

  • Review the data on efficacy and safety of IL-17A and IL-23 inhibitors in axSpA/AS

  • Evaluate tools for the assessment of disease activity and monitoring of treatment responses in axSpA/AS

  • Discuss treat-to-target and personalized medicine approaches in axSpA/AS

Faculty: Joerg Ermann, MD
Associate Physician
Division of Rheumatology, Immunology and Allergy
Brigham and Women’s Hospital
Instructor in Medicine
Harvard Medical School


Dr.Ermann has served on an advisory board for Eli Lilly, Novartis, Pfizer, and UCB. He has received grants or research from Boehringer Ingelheim and Pfizer. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Lilly and Novartis Pharmaceuticals Corporation

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue